Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Prohibitin is a prognostic marker of relapse and therapeutic target to block chemotherapy resistance in Wilms tumor

Item Type:Preprint
Title:Prohibitin is a prognostic marker of relapse and therapeutic target to block chemotherapy resistance in Wilms tumor
Creators Name:Ortiz, M.V. and Ahmed, S. and Burns, M. and Henssen, A.G. and Hollmann, T.J. and MacArthur, I. and Gunasekera, S. and Gaewsky, L. and Bradwin, G. and Ryan, J. and Letai, A. and He, Y. and Naranjo, A. and Chi, Y.Y. and LaQuaglia, M. and Heaton, T. and Cifani, P. and Dome, J.S. and Gadd, S. and Perlman, El. and Mullen, E. and Steen, H. and Kentsis, A.
Abstract:Wilms tumor (WT) is the most common childhood kidney cancer. To improve risk stratification and identify novel therapeutic targets for patients with WT, we used high-resolution mass spectrometry proteomics to identify urine tumor markers associated with WT relapse. We determined urine proteomes at diagnosis of 49 patients with WT, non-WT renal tumors, and age-matched controls, leading to the quantitation of 6,520 urine proteins. Supervised analysis revealed specific urine markers of renal rhabdoid tumors, kidney clear cell sarcomas, renal cell carcinomas, as well as those detected in cured and relapsed WT. In particular, urine prohibitin was significantly elevated at diagnosis in patients with relapsed as compared to cured WT. In a validation cohort of 139 patients, a specific urine prohibitin enzyme-linked immunosorbent assay demonstrated that prohibitin concentrations greater than 998 ng/mL at diagnosis were significantly associated with ultimate WT relapse. Immunohistochemical analysis revealed that prohibitin was highly expressed in primary WT specimens and associated with disease stage. Using functional genetic experiments, we found that prohibitin was required for the growth and survival of WT cells. Overexpression of prohibitin was sufficient to block intrinsic mitochondrial apoptosis and to cause resistance to diverse chemotherapy drugs, at least in part by dysregulating factors that control apoptotic cytochrome c release from mitochondrial cristae. Thus, urine prohibitin may improve therapy stratification, non-invasive monitoring of treatment response and early disease detection. In addition, therapeutic targeting of chemotherapy resistance induced by prohibitin dysregulation may offer improved therapies for patients with Wilms and other relapsed or refractory tumors.
Source:bioRxiv
Publisher:Cold Spring Harbor Laboratory Press (U.S.A.)
Article Number:508754
Date:30 December 2018
Official Publication:https://doi.org/10.1101/508754
Related to:
URLURL Type
https://edoc.mdc-berlin.de/18378/Final version

Repository Staff Only: item control page

Open Access
MDC Library